The World Health Organization announced Tuesday it has officially adopted the first-ever "Pandemic Agreement," just as the ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international alliances.

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...